Literature DB >> 24247905

Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation.

Stefan Reuter1, Barbara Heitplatz, Hermann Pavenstädt, Barbara Suwelack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24247905     DOI： 10.1097/01.TP.0000435705.63428.1f

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  7 in total

1.  End-stage renal disease from hemolytic uremic syndrome in the United States, 1995-2010.

Authors:  Donal J Sexton; Scott Reule; Craig A Solid; Shu-Cheng Chen; Allan J Collins; Robert N Foley
Journal:  Hemodial Int       Date:  2015-02-17       Impact factor: 1.812

Review 2.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

Review 3.  Advances and challenges in the management of complement-mediated thrombotic microangiopathies.

Authors:  Jean-Claude Davin; Nicole C A J van de Kar
Journal:  Ther Adv Hematol       Date:  2015-08

Review 4.  Complement regulator CD46: genetic variants and disease associations.

Authors:  M Kathryn Liszewski; John P Atkinson
Journal:  Hum Genomics       Date:  2015-06-10       Impact factor: 4.639

5.  Atypical Hemolytic Uremic Syndrome Recurrence after Renal Transplantation: C3-Glomerulonephritis as an Initial Presentation.

Authors:  Yassine Bouatou; Véronique Frémeaux Bacchi; Jean Villard; Solange Moll; Pierre-Yves Martin; Karine Hadaya
Journal:  Transplant Direct       Date:  2015-03-26

Review 6.  Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.

Authors:  Kioa L Wijnsma; Caroline Duineveld; Jack F M Wetzels; Nicole C A J van de Kar
Journal:  Pediatr Nephrol       Date:  2018-11-06       Impact factor: 3.714

7.  First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient.

Authors:  Ulrich Jehn; Ugur Altuner; Hermann Pavenstädt; Stefan Reuter
Journal:  Transpl Int       Date:  2022-10-03       Impact factor: 3.842
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.